Avelumab plus BSC significantly improved OS and PFS in advanced urothelial carcinoma patients, irrespective of diabetes status, as shown in the JAVELIN Bladder 100 trial. The trial's findings led to ...

Bavencio shows efficacy and safety in advanced urothelial carcinoma, regardless of diabetes status, as per JAVELIN Bladder 100 trial findings. Diabetes requires careful management in patients ...

Immunocompromised patients with bladder had a higher risk of disease progression and recurrence when compared to their non-immunocompromised counterparts. Immunocompromised patients with bladder ...

100% (n=7) of evaluable patients (1 CIS, 6 Ta/T1) achieved disease free status. One of these patients was re-treated at 3 months. “I am impressed by these promising NDV-01 data reported at AUA2025.

Study showing that Decipher GRID-derived PORTOS signature predicts benefit from dose-escalated radiation therapy also published in Annals of Oncology “The breadth and depth of Decipher-focused data ...